Clinical Trials Logo

Ovarian Epithelial Carcinoma clinical trials

View clinical trials related to Ovarian Epithelial Carcinoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05763199 Recruiting - Clinical trials for Fallopian Tube Carcinoma

Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy

Start date: December 1, 2023
Phase: Phase 2
Study type: Interventional

This is a pilot phase, randomized, double-blinded feasibility pilot study of AHCC in participants with ovarian cancer.

NCT ID: NCT04794322 Recruiting - Ovarian Neoplasms Clinical Trials

Developing a Test for the Detection of Ovarian Cancer

Start date: April 13, 2020
Phase:
Study type: Observational

The study aims to develop a test for early detection of ovarian cancer using DNA from a growth involving the ovary found in a washing of the uterus (womb), and proteins found in the blood. The samples of the wash and the blood will be taken before surgery. After surgery, doctors will determine whether the participant had ovarian cancer or a benign disease of the ovaries. The tests of the washings and the blood will be examined to see how much the participants with ovarian cancer can be separated from the participants with a benign ovarian disease by the tests. Small amounts from the washing and the blood samples will be sent to four sites for analysis. Statistical analyses of these data will compare tumor DNA found in the washing of the uterus with proteins in the blood to detect cases of ovarian cancer. The primary goal is to find tests that are mostly positive for cases of ovarian cancer and mostly negative for patients with benign disease. It is hoped that if the tests work for participants with symptoms of the disease that these tests will also work when testing women who have no symptoms. A new study would be needed to see if the tests worked in this situation. If the tests work, this could lead to increasing the number of cases detected in early stage disease and decreasing the number of cases detected in late stage disease. If this change in late stage is large, it will likely reduce deaths due to ovarian cancer.